Dr Clara M Keegan, MD | |
3 Timber Ln, South Burlington, VT 05403-7205 | |
(802) 847-8500 | |
(802) 847-6140 |
Full Name | Dr Clara M Keegan |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 22 Years |
Location | 3 Timber Ln, South Burlington, Vermont |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770542631 | NPI | - | NPPES |
967199 | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 219879 (Massachusetts) | Secondary |
207Q00000X | Family Medicine | 042-0012154 (Vermont) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Uvmhn Home Health And Hospice | Colchester, VT | Home health agency |
Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
A predicted population drop at the end of the century could be explained by stress from meaningless social interactions, according to a review article published in the Endocrine Society's journal, Endocrinology.
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis
Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer - one of a handful identified to date in Caucasians.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
› Verified 9 days ago
Entity Name | University Of Vermont Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
A predicted population drop at the end of the century could be explained by stress from meaningless social interactions, according to a review article published in the Endocrine Society's journal, Endocrinology.
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis
Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer - one of a handful identified to date in Caucasians.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Clara M Keegan, MD 3 Timber Ln, South Burlington, VT 05403-7205 Ph: (802) 847-8500 | Dr Clara M Keegan, MD 3 Timber Ln, South Burlington, VT 05403-7205 Ph: (802) 847-8500 |
News Archive
A predicted population drop at the end of the century could be explained by stress from meaningless social interactions, according to a review article published in the Endocrine Society's journal, Endocrinology.
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis
Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer - one of a handful identified to date in Caucasians.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
› Verified 9 days ago
Kate Lamancuso, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Timber Ln, South Burlington, VT 05403 Phone: 802-847-8500 Fax: 802-847-6140 | |
Dr. Sepinoud Bazel, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 20 Kimball Ave Ste 303, South Burlington, VT 05403 Phone: 802-495-5817 | |
David Lisle, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 192 Tilley Dr, Orthopaedic Specialty Center, South Burlington, VT 05403 Phone: 802-847-2663 | |
Dr. Robert A Luebbers, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 Williston Rd, South Burlington, VT 05403 Phone: 802-847-8500 Fax: 802-847-6140 | |
Micheal R Sirois, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1775 Williston Rd, South Burlington, VT 05403 Phone: 802-847-8500 Fax: 802-860-4324 | |
Mrs. Kathryn Ridgely Applegate, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 118 Tilley Dr Ste 201, South Burlington, VT 05403 Phone: 802-847-5550 | |
Dr. Aaron W Reiter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Timber Ln, South Burlington, VT 05403 Phone: 802-847-7200 |